American Association for Cancer Research

AACR Press Releases

American Association for Cancer Research to Inaugurate the First Class of the Fellows of the AACR Academy


March 25, 2013

Bookmark and Share

PHILADELPHIA — The American Association for Cancer Research will inaugurate the first class of the Fellows of the AACR Academy at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

The AACR Academy has been created to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. These Fellows have been selected through a rigorous peer review process that evaluates individuals on the basis of their stellar scientific achievements in cancer research.

“Our Board of Directors made the decision to establish the AACR Academy as a mechanism for recognizing scientists whose contributions to the cancer field have had an extraordinary impact. Membership in the Fellows of the AACR Academy will be the most prestigious honor bestowed by the American Association for Cancer Research,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR.

The Fellows of the AACR Academy is a separate entity within the American Association for Cancer Research, and only individuals who have made exceptional contributions to cancer and/or cancer-related biomedical science are eligible for election.

The inaugural class of Fellows will be inducted into the AACR Academy on Friday, April 5, at the National Museum of Women in the Arts in Washington, D.C., at 6:30 p.m. Reporters who wish to attend this dinner must RSVP to Jeremy Moore, associate director of media relations at the AACR, at jeremy.moore@aacr.org no later than March 28.  

The induction ceremony will be followed by a meeting of the Academy on Saturday, April 6, and special recognition of the inaugural Fellows during the opening plenary session on Sunday, April 7. These events will be annual occurrences at future AACR Annual Meetings.

The inaugural class of Fellows of the AACR Academy will consist of 106 individuals, symbolizing the age of the organization upon establishment of the Academy.

Future classes of Fellows shall consist of no more than 11 individuals, in honor of the 11 founding members of the American Association for Cancer Research. These Fellows will be elected by a vote of all the Fellows of the AACR Academy.

The inaugural Fellows of the AACR Academy are:

  • Karen H. Antman, M.D., John Sandson Professor of Health Sciences; Dean, Boston University School of Medicine; Provost, Boston University Medical Campus
  • David Baltimore, Ph.D., Robert Andrews Millikan Professor of Biology, President Emeritus, California Institute of Technology
  • Françoise Barré-Sinoussi, Ph.D., Professor and Director, Regulation of Retroviral Infections Unit, Virology Department, Institut Pasteur
  • Paul Berg, Ph.D., Cahill Professor of Biochemistry, Emeritus, Stanford University School of Medicine
  • Joseph R. Bertino, M.D., American Cancer Society Professor; Chief Scientific Officer, The Cancer Institute of New Jersey; University Professor of Medicine & Pharmacology, UMDNJ-RWJMS; Interim Director, The Stem Cell Institute of N.J.
  • J. Michael Bishop, M.D., Professor, Department of Microbiology and Immunology; Director, G. W. Hooper Research Foundation; Chancellor Emeritus, University of California, San Francisco
  • Mina J. Bissell, Ph.D., Distinguished Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory
  • Elizabeth H. Blackburn, Ph.D., Morris Herzstein Endowed Chair in Biology and Physiology and Professor, Departments of Biochemistry/Biophysics and Microbiology/Immunology, University of California, San Francisco
  • Sydney Brenner, MB.BCh., D.Phil., Founder, Acidophil, LLC; Senior Distinguished Fellow of the Crick-Jacobs Center, Salk Institute for Biological Studies
  • Angela H. Brodie, Ph.D., Professor of Pharmacology, University of Maryland School of Medicine; Investigator, University of Maryland Marlene and Stewart Greenebaum Cancer Center
  • Mario R. Capecchi, Ph.D., Distinguished Professor, Human Genetics and Biology, University of Utah School of Medicine; Investigator, Howard Hughes Medical Institute
  • Webster K. Cavenee, Ph.D., Director, Ludwig Institute for Cancer Research; Distinguished Professor, University of California, San Diego
  • Martin Chalfie, Ph.D., William R. Kenan, Jr. Professor of Biological Sciences, Department of Biological Sciences, Columbia University
  • Zhu Chen, M.D., Ph.D., Vice-Chairman, 12th Standing Committee of the National People’s Congress; Chairman, 15th Chinese Peasants and Workers Democratic Party, Central Committee
  • Aaron J. Ciechanover, M.D., D.Sc., Distinguished Research Professor, Technion-Israel Institute of Technology
  • Bayard D. Clarkson, M.D., Member and Head, Laboratory of Hematopoietic Cell Kinetics, Memorial Sloan-Kettering Cancer Center
  • Donald S. Coffey, Ph.D., Catherine Iola and J. Smith Michael Distinguished Professor of Urology, Johns Hopkins University School of Medicine
  • Stanley N. Cohen, M.D., Kwoh-Ting Li Professor in the School of Medicine, Professor of Genetics, and Professor of Medicine, Stanford University
  • Suzanne Cory, Ph.D., Honorary Distinguished Professorial Fellow, Molecular Genetics of Cancer Division, Walter and Eliza Hall Institute of Medical Research and Vice-Chancellor’s Fellow, University of Melbourne
  • Carlo M. Croce, M.D., Professor and Chair, Department of Molecular Virology, Immunology and Medical Genetics; Director, Institute of Genetics, The Ohio State University School of Medicine
  • Tom Curran, Ph.D., Deputy Scientific Director, Division of Cancer Pathobiology; Mai and Harry F. West Chair in Pediatric Research, The Children's Hospital of Philadelphia Research Institute; Professor of Pathology and Laboratory Medicine, Cell and Developmental Biology, Perelman School of Medicine; Associate Director, Translational Genomics, University of Pennsylvania
  • Brian J. Druker, M.D., Director, Knight Cancer Institute, Oregon Health and Science University; JELD-WEN Chair of Leukemia Research; Investigator, Howard Hughes Medical Institute
  • Raymond N. DuBois, M.D., Ph.D., Executive Director, The Biodesign Institute; Dalton Chair, School of Health Solutions, Arizona State University
  • Sir Martin J. Evans, Ph.D., Chancellor, Cardiff University
  • Emmanuel Farber, M.D., Ph.D., Chairman Emeritus and Professor, Department of Pathology, University of Toronto
  • Napoleone Ferrara, M.D., Distinguished Professor of Pathology, Senior Deputy Director for Basic Sciences, Moores Cancer Center, University of California, San Diego
  • Isaiah J. Fidler, D.V.M., Ph.D., Professor, Department of Cancer Biology, R.E. "Bob" Smith Distinguished Chair in Cell Biology, Head, Cancer Metastasis Laboratory, The University of Texas MD Anderson Cancer Center
  • Bernard Fisher, M.D., Distinguished Service Professor, Department of Surgery, University of Pittsburgh
  • Joseph F. Fraumeni Jr., M.D., Senior Investigator and Advisor, Division of Cancer Epidemiology and Genetics, National Cancer Institute
  • Emil Frei III, M.D., Physician-in-Chief Emeritus, Richard and Susan Smith Distinguished Professor of Medicine Emeritus, Dana-Farber Cancer Institute, Harvard Medical School
  • Elaine V. Fuchs, Ph.D., Rebecca C. Lancefield Professor, Laboratory of Mammalian Cell Biology and Development, Rockefeller University; Investigator, Howard Hughes Medical Institute
  • Judy E. Garber, M.D., M.P.H., Director, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School
  • Walter Gilbert, Ph.D., Carl M. Loeb University Professor Emeritus, Department of Molecular and Cellular Biology, Harvard University
  • Alfred G. Gilman, M.D., Ph.D., Regental Professor of Pharmacology Emeritus, University of Texas Southwestern Medical Center
  • Carol W. Greider, Ph.D., Daniel Nathans Professor and Director, Department of Molecular Biology and Genetics; Professor of Oncology, Johns Hopkins University School of Medicine
  • Roger C. L. Guillemin, M.D., Ph.D., Distinguished Professor, Salk Institute for Biological Studies
  • Sir John B. Gurdon, D.Phil., Distinguished Group Leader, Wellcome Trust/Cancer Research U.K. Gurdon Institute
  • William N. Hait, M.D., Ph.D., Global Head at Janssen Research and Development, LLC
  • Leland H. Hartwell, Ph.D., Virginia G. Piper Chair of Personalized Medicine, Chief Scientist, Center for Sustainable Health, Biodesign Institute, Arizona State University; President Emeritus, Fred Hutchinson Cancer Research Center
  • Avram Hershko, M.D., Ph.D., Distinguished Professor at the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Adjunct Professor of Pathology, New York University School of Medicine
  • James F. Holland, M.D., Distinguished Professor of Neoplastic Diseases, Mount Sinai Medical Center
  • Jimmie C. Holland, M.D., Wayne E. Chapman Chair in Psychiatric Oncology; Attending Psychiatrist, Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center
  • Waun Ki Hong, M.D., Vice Provost, Clinical Research; Head, Division of Cancer Medicine; Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center
  • Leroy E. Hood, M.D., Ph.D., President and Co-founder, Institute for Systems Biology; Full Member, University of Washington Molecular and Cellular Biology Program; Professor at Large, Keck Graduate Institute of Applied Life Sciences
  • H. Robert Horvitz, Ph.D., David H. Koch Professor of Biology, Massachusetts Institute of Technology; Member, MIT Koch Institute for Integrative Cancer Research; Member, MIT McGovern Institute for Brain Research; Investigator, Howard Hughes Medical Institute
  • Susan Band Horwitz, Ph.D., Distinguished Professor, Rose C. Falkenstein Chair in Cancer Research, Associate Director for Therapeutics, Albert Einstein Cancer Center; Co-Chair, Department of Molecular Pharmacology, Albert Einstein College of Medicine
  • Sir R. Timothy Hunt, Ph.D., Emeritus Group Leader, Clare Hall Laboratories, Cancer Research U.K.
  • Tony Hunter, Ph.D., Director, Salk Institute Cancer Center; American Cancer Society Professor of Molecular and Cell Biology, Renato Dulbecco Chair, The Salk Institute for Biological Studies
  • Tyler Jacks, Ph.D., Director, David H. Koch Institute for Integrative Cancer Research; Professor of Biology, Massachusetts Institute of Technology; Investigator, Howard Hughes Medical Institute
  • Peter A. Jones, Ph.D., D.Sc., Distinguished Professor of Urology and Biochemistry & Molecular Biology; Mark A, J. Ruth, and Stillman F. Sawyer Chair in Cancer Research, University of Southern California (USC) Norris Comprehensive Cancer Center
  • V. Craig Jordan, Ph.D., D.Sc., Professor of Oncology and Pharmacology, Vincent T. Lombardi Chair of Translational Cancer Research, Vice Chair, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University
  • Yuet Wai Kan, M.D., Louis K. Diamond Professor of Hematology, Departments of Laboratory Medicine and Medicine, University of California, San Francisco
  • Mary-Claire King, Ph.D., American Cancer Society Professor, Departments of Medicine and Genome Sciences, University of Washington
  • Eva Klein, M.D., Ph.D., Professor Emeritus, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
  • George Klein, M.D., Ph.D., Professor Emeritus, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
  • Alfred G. Knudson Jr., M.D., Ph.D., Distinguished Scientist and Senior Advisor to the President, Fox Chase Cancer Center
  • Brian K. Kobilka, M.D., Professor, Molecular and Cellular Physiology and Medicine, Stanford University School of Medicine
  • Margaret L. Kripke, Ph.D., Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas; Vivian L. Smith Distinguished Chair in Immunology Emerita and Professor Emerita, Department of Immunology, and Professor Emerita, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center
  • Philip Leder, M.D., Professor Emeritus, Department of Genetics, Harvard Medical School
  • Robert J. Lefkowitz, M.D., Investigator, Howard Hughes Medical Institute; James B. Duke Professor of Medicine; Professor of Biochemistry and Chemistry, Duke University Medical Center
  • Arnold J. Levine, Ph.D., Professor, Simons Center for Systems Biology, Institute for Advanced Study; Professor, Cancer Institute of New Jersey
  • Lawrence A. Loeb, M.D., Ph.D., Professor of Pathology, Biochemistry and Director, Joseph Goldstein Memorial Cancer Research Laboratory, University of Washington School of Medicine
  • Tak W. Mak, Ph.D., Director, Advanced Medical Discovery Institute and Director, The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, Princess Margaret  Cancer Centre; Professor, Departments of Medical Biophysics and Immunology, University of Toronto
  • Lynn M. Matrisian, Ph.D., Vice President, Scientific and Medical Affairs, Pancreatic Cancer Action Network
  • Frank McCormick, Ph.D., Director, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine, University of California, San Francisco
  • John Mendelsohn, M.D., Director, Sheik Kalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and Past President, MD Anderson Cancer Center
  • Donald Metcalf, M.D., Professor Emeritus, University of Melbourne; Carden Fellow in Cancer Research, Division of Cancer and Hematology, the Walter and Eliza Hall Institute of Medical Research
  • Enrico Mihich, M.D., Presidential Scholar and Special Assistant to the President for Sponsored Research, Dana-Farber Cancer Institute
  • Beatrice Mintz, Ph.D., Professor and Jack Schultz Chair in Basic Research, Fox Chase Cancer Center
  • Luc Montagnier, M.D., Co-Founder and President, World Foundation for AIDS Research and Prevention; Director of Research Emeritus, Centre National de la Recherché Scientifique; Professor Emeritus, Pasteur Institute
  • Harold L. Moses, M.D., Hortense B. Ingram Professor of Molecular Oncology; Professor of Cancer Biology, Medicine and Pathology; Director Emeritus, Vanderbilt-Ingram Comprehensive Cancer Center
  • Sir Paul M. Nurse, Ph.D., Director, Francis Crick Institute, London; President, The Royal Society
  • Olufunmilayo I. Olopade, M.D., Walter L. Palmer Distinguished Service Professor of Medicine & Human Genetics; Associate Dean for Global Health; Director, Center for Clinical Cancer Genetics, University of Chicago Pritzker School of Medicine
  • Arthur B. Pardee, Ph.D., Professor of Biological Chemistry and Molecular Pharmacology Emeritus, Harvard Medical School
  • Martine J. Piccart, M.D., Ph.D., Professor of Oncology, Université Libre de Bruxelles; Director of Medicine, Jules Bordet Institute
  • Sir Bruce A. J. Ponder, MB.BChir., Ph.D., Founding Director, Cancer Research U.K. Cambridge Research Institute; Professor and Head of Oncology, University of Cambridge; Honorary Consultant Physician, Cambridge University Hospitals
  • Sir Richard J. Roberts, Ph.D., Chief Scientific Officer, New England Biolabs, Inc.
  • Irwin A. Rose, Ph.D., Distinguished Professor Emeritus, Department of Physiology and Biophysics, University of California, Irvine
  • Janet D. Rowley, M.D., Blum-Riese Distinguished Professor of Medicine, Molecular Genetics and Cell Biology, and Human Genetics, University of Chicago
  • Frederick Sanger, Ph.D., Emeritus Professor, Laboratory for Molecular Biology, University of Cambridge
  • Alan C. Sartorelli, Ph.D., Alfred Gilman Professor of Pharmacology, Yale University School of Medicine
  • Andrew V. Schally, Ph.D., Distinguished Medical Research Scientist; Head, Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Department of Veterans Affairs; Distinguished Leonard M. Miller Professor of Pathology, Miller School of Medicine, University of Miami
  • Phillip A. Sharp, Ph.D., Institute Professor and Faculty Member, David H. Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology
  • Charles J. Sherr, M.D., Ph.D., Herrick Foundation Chair, Department of Tumor Cell Biology, St. Jude Children’s Research Hospital; Investigator, Howard Hughes Medical Institute
  • Osamu Shimomura, Ph.D., Distinguished Scientist, Marine Biological Laboratory; Professor of Physiology Emeritus, Boston University School of Medicine    
  • Dennis J. Slamon, M.D., Ph.D., Director, Clinical/Translational Research; Director, Revlon/UCLA Women’s Cancer Research Program, Jonsson Comprehensive Cancer Center; Professor of Medicine; Chief of the Division of Hematology/Oncology; Executive Vice Chair for Research, David Geffen School of Medicine, University of California, Los Angeles    
  • Oliver Smithies, D.Phil., Weatherspoon Eminent Distinguished Professor, University of North Carolina School of Medicine at Chapel Hill
  • Michael B. Sporn, M.D., Professor of Pharmacology and Medicine, Geisel School of Medicine at Dartmouth
  • Louise C. Strong, M.D., Sue and Radcliffe Killam Chair, Department of Genetics, and Professor, Department of Genetics, The University of Texas MD Anderson Cancer Center
  • Takashi Sugimura, M.D., President, Toho University; President Emeritus, National Cancer Center
  • Sir John E. Sulston, Ph.D., Professor and Chair of the Institute for Science, Ethics and Innovation, University of Manchester
  • Jack W. Szostak, Ph.D., Investigator, Howard Hughes Medical Institute; Professor of Genetics, Harvard Medical School; Professor of Chemistry and Chemical Biology, Harvard University; Alexander Rick Distinguished Investigator, Department of Molecular Biology, Massachusetts General Hospital
  • Roger Y. Tsien, Ph.D., Professor of Pharmacology, Chemistry and Biochemistry, University of California, San Diego; Investigator, Howard Hughes Medical Institute
  • Arthur C. Upton, M.D., Emeritus Professor of Environmental Medicine and Clinical Professor of Environmental and Community Medicine, University of Medicine and Dentistry, Robert Wood Johnson Medical School
  • George F. Vande Woude, Ph.D., Distinguished Scientific Fellow, Van Andel Research Institute
  • Bert Vogelstein, M.D., Clayton Professor of Oncology and Pathology, Howard Hughes Medical Institute Investigator, Director of the Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Kimmel Comprehensive Cancer Center
  • Peter K. Vogt, Ph.D., Executive Vice President for Scientific Affairs; Professor, Department of Molecular and Experimental Medicine; The Scripps Research Institute
  • Daniel D. Von Hoff, M.D., Physician in Chief, Distinguished Professor, Translational Genomics Research Institute; Professor of Medicine, Mayo Clinic; Chief Scientific Officer, Scottsdale Health Care; Professor, University of Arizona College of Pharmacy
  • Geoffrey M. Wahl, Ph.D., Professor, Gene Expression Laboratory; Daniel and Martina Lewis Chair, Salk Institute for Biological Studies
  • James D. Watson, Ph.D., Chancellor Emeritus, Cold Spring Harbor Laboratory
  • Lee W. Wattenberg, M.D., Professor of Laboratory Medicine and Pathology Emeritus, Masonic Cancer Center, University of Minnesota
  • Robert A. Weinberg, Ph.D., Member, Whitehead Institute for Biomedical Research; Professor, Department of Biology, Massachusetts Institute of Technology; Director, Ludwig/MIT Center for Molecular Oncology
  • John H. Weisburger, Ph.D., Research Professor of Pathology, Graduate School of Basic Medical Sciences, New York Medical College
  • Jane Cooke Wright, M.D., Deceased (1919 – 2013)
  • Shinya Yamanaka, M.D., Ph.D., Director and Professor, Center for iPS Cell Research and Application, Kyoto University; Senior Investigator, Gladstone Institute of Cardiovascular Disease; and Professor of Anatomy, University of California, San Francisco    
  • Harald zur Hausen, M.D., Professor Emeritus, German Cancer Research Center
# # #

Press registration for the AACR Annual Meeting 2013 is free to qualified journalists and public information officers.

Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

Media Contact:
Jeremy Moore
(215) 446-7109
Jeremy.Moore@aacr.org